| News

Investments in Basel start-ups on the rise

21.10.2019

Start-ups established in Basel raised more than 200 million euro in investments during the first half of 2019. Basel therefore leads the way in this regard within Switzerland, and stands in eighth place across Europe, as revealed by a new EY study.

Start-up (img: Ken Easter/shutterstock)

The consultancy firm EY has presented its latest Start-up-Barometer Europe. This study analyzes the equity financing of European start-ups. Across Europe, a total of 16.9 billion euro was accordingly invested in start-ups during the first half of 2019. This represents growth of 62 percent in comparison with the same period of last year. This increase was also replicated in Switzerland, and in Basel in particular.

While a total of 592 million euro in investments (H1 2018: 405 million euro) secures fifth place for Switzerland in the country rankings, Basel was ranked among the top ten for the first time, taking eighth place in the process. Following on from a total of 24 million euro in the first half of 2018, the equivalent value for the first six months of the current year stood at 203 million euro. London (5.7 billion euro), Paris (2.2 billion euro) and Berlin (1.9 billion euro) took the top three positions respectively. In Switzerland, two other cities made their way into the top 20: Zurich was ranked in 16th position (117 million euro vs. 160 million euro in the same period of the previous year), while Lausanne (97 million euro) came in 19th place.

One start-up, namely Arvelle Therapeutics, made a particularly great contribution to Basel’s high ranking. No other Swiss start-up raised more money from investment during the first half of 2019 (169 million euro) than the spin-off of the Basel-based Axovant Sciences, which in turn form part of Roivant Sciences. Arvelle specializes in treatments for the central nervous system. Having raised a total of 21 million euro, Polyneuron Pharmaceuticals, which is also based in Basel, took fifth place among Swiss companies.

EY also analyzed the number of financing rounds for its study. Here, Switzerland also came in fifth place with a total of 150 rounds. As was the case in terms of investment volume, Switzerland is behind the UK (537 rounds; 6.6 billion euro), France (387 rounds; 2.8 billion euro), Germany (331 rounds; 2.6 billion euro) and Sweden (163 rounds; 1.3 billion euro). Zurich leads the way among Swiss cities for rounds of financing, taking fifth place (48 rounds) in the European rankings. Here, London again tops the charts with 323 rounds.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel is “probably the most productive life sciences location in the world”

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area cantons publish joint economic report

The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.

Read More
Basel Area Business & Innovation, Innovation

Resistell receives high-level EU grant

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Read More
Novartis Campus
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.